OC: Molecular Characterization of Candida Auris

• Sponsor: Islamia University of Bahawalpur (Other)
• Overall Status: Completed
• CT.gov ID: NCT04121871
• Collaborator: (none)
• Enrollment: 384
• Locations: 2
• Actual Duration (Months): 3.5
• Patients Per Site: 192
• Patients Per Site Per Month: 55.1

Study Details

Study Description

Brief Summary

Candida auris is emerging fungal opportunistic pathogen in developing countries. Much studies has been conducted on Candida albicans. there was a dire need to investigate this alarming threat. Our hypothesis is that by recording the patients diagnosed with oropharygneal candidiasis and collecting clinical swab samples from these patients will be fruitful if microbiological isolation, identification and molecular characterization will be done. So this is the first study on C. auris in south punjab, Pakistan. Aim of this study is to collect epidemiological data of C. auris.

Condition or Disease	Intervention/Treatment	Phase
Oral Fungal Infection	Other: No intervention

Study Design

• Study Type: Observational
• Actual Enrollment: 384 participants
• Observational Model: Other
• Time Perspective: Cross-Sectional
• Official Title: Formulation Development and In-Vitro Studies of Efficacy of Botanical Extracts Against Candida Auris
• Actual Study Start Date: Nov 15, 2019
• Actual Primary Completion Date: Feb 29, 2020
• Actual Study Completion Date: Feb 29, 2020

Outcome Measures

Primary Outcome Measures

1. Prevalence of C. auris [From November 15, 2019 to February 29, 2020]

   patients from selected localities will be recorded along with total patients in that category, prevalence will be calculated on the record collected from specified duration of study

2. Seasonality of C. auris infection [From November 15, 2019 to February 29, 2020]

   Number of patients recorded during different months will be the source of calculation of seasonality index of the C. auris infection

3. Drug susceptibility [From November 15, 2019 to February 29, 2020]

   Antifungal drug discs will be used for assessing the antfungal drugs susceptibility

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A to 100 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Pre-diagnosed Patients of both gender from pre-selected localities

Exclusion Criteria:

• Healthy individuals or individuals having no oral fungal infection individuals above 100 years of age

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Bahawal Victoria Hospital Bahawalpur	Bahawalpur	Punjab	Pakistan	63100
2	Civil Hospital Jhangi Wala Road Bahawalpur	Bahawalpur	Punjab	Pakistan	63100

Sponsors and Collaborators

• Islamia University of Bahawalpur

Investigators

• Principal Investigator: Jafi H Shirazi, M.Phil, The Islamia University of Bahawalpur

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Jafir Hussain Shirazi, Principal Investigator, Islamia University of Bahawalpur
• ClinicalTrials.gov Identifier: NCT04121871
• Other Study ID Numbers: Oral Fungal Infection
• First Posted: Oct 10, 2019
• Last Update Posted: Oct 27, 2020
• Last Verified: Oct 1, 2020

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Jafir Hussain Shirazi, Principal Investigator, Islamia University of Bahawalpur: Candida auris; Oral Fungal Infection; Candidiasis
• Additional relevant MeSH terms: Mycoses

Study Results

No Results Posted as of Oct 27, 2020